AbbVie is commercializing its new lymphoma treatment Epkinly in the US and as Tepkinly in other markets. This product addresses an unmet need for patients who have failed multiple prior treatments, strengthening its position in hematologic oncology.
Filing excerpt
Epkinly (epcoritamab) is a product used to treat adults with certain types of diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma that has recurred or that does not respond to previous treatment after receiving two or more treatments... It is marketed as Epkinly in the United States and primarily as Tepkinly outside of the United States.
What this signalsFilings often name leadership changes, deals and spending plans.
Regions named
sec-10kproductLaunchGet every 10-K signal for AbbVie and the companies you sell to, in the tools you already use.
Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at AbbVie this week?”
The Signal API returns 10-K signals for any list of companies as JSON, for your CRM, warehouse or app.
Sign up and spend your free credits on the companies you sell to.
This page shows a preview. The full sec-10k record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.
Company
linkedin_urlValue in the APIindustriesValue in the APIemployee_count_lowValue in the APIemployee_count_highValue in the APIrevenueValue in the APIdescriptionValue in the APISignal
signal_nameValue in the APIassociationValue in the APIGET /v1/signals/91ac78b4-6f22-469e-bd95-7dbc475f0241 returns this record as JSON. POST /v1/companies/enrich returns every signal for abbvie.com.
{
"signal_id": "91ac78b4-6f22-469e-bd95-7dbc475f0241",
"signal_type": "sec-10k",
"signal_subtype": "productLaunch",
"detected_at": "2026-02-24T09:18:27.385+00:00",
"company": {
"name": "AbbVie",
"domain": "abbvie.com"
},
"data": {
"detail": "AbbVie is commercializing its new lymphoma treatment Epkinly in the US and as Tepkinly in other markets. This product addresses an unmet need for patients who have failed multiple prior treatments, strengthening its position in hematologic oncology.",
"metrics": {
"timeframe": "current_year"
},
"summary": "AbbVie launches Epkinly/Tepkinly, a new treatment for relapsed or refractory lymphoma.",
"excerpts": "Epkinly (epcoritamab) is a product used to treat adults with certain types of diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma that has recurred or that does not respond to previous treatment after receiving two or more treatments... It is marketed as Epkinly in the United States and primarily as Tepkinly outside of the United States.",
"relevance": 0.9,
"sentiment": "positive",
"confidence": "high",
"source_url": "https://www.sec.gov/Archives/edgar/data/1551152/000155115226000008/abbv-20251231.htm",
"filing_date": "2026-02-20",
"filing_year": 2026,
"fiscal_year_end": "12/31",
"sales_relevance": "Go-to-market support",
"signal_category": "strategic",
"regions_mentioned": [
"United States"
]
}
}
curl https://signals.autobound.ai/v1/signals/91ac78b4-6f22-469e-bd95-7dbc475f0241 \
-H "X-API-KEY: $AUTOBOUND_API_KEY"curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"abbvie.com","limit":20}'Long text fields are shortened on this page.
Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.